MedWorld Advisors 5/4/22 MedWorld Advisors 5/4/22

M&A in Turbulent Times—Bullish or Bearish?

M&A deal volume in the medical device contract manufacturing market rebounded dramatically last year, reaching a record $1.6 billion. But it remains to be seen how long the 2021 M&A recovery will last—will 2022’s deal value top last year’s or will the upturn lose steam as the seasons progress and the world grapples with lingering supply chain issues, 40-year-high inflation (U.S.), and an increasingly bloody war in Ukraine?

Estelle Black 4/27/22 Estelle Black 4/27/22

Daniel Sheppard to Speak at 10X Conference in San Diego, CA

Daniel Sheppard to speak at the 10X Conference in San Diego, CA May 12, 2022.

MedWorld Advisors 4/13/22 MedWorld Advisors 4/13/22

What’s Your Ukraine Strategy?

What you do for Ukraine matters to all of us!

MedWorld Advisors 4/5/22 MedWorld Advisors 4/5/22

Strategy or Tactics—What Should be the Focus for Medtech in 2022?

Successful business executives know strategy is important, but they also understand the most effective plans focus on winning methods. So what should be the focus for Medtech in 2022? Strategy or tactics?

Estelle Black 3/28/22 Estelle Black 3/28/22

What’s Your China Strategy?

The post-pandemic 2022 may be a new strategic inflection point for many organizations relative to their China strategy. This leads to the question for MedTech businesses: What is your China strategy going forward?

Estelle Black 3/22/22 Estelle Black 3/22/22

Who's Your Buyer? A Look Into The Most Common Types of Buyers In A Business Acquisition - A Podcast

A discussion on the most common, active types of buyers we've been seeing in this market when it comes to business acquisition. Medworld Advisors Managing Director and Co-Founder, Dave Sheppard, brings great insights about what each different type of buyer is looking for in terms of price, terms, transaction timelines & more.

MedWorld Advisors 3/7/22 MedWorld Advisors 3/7/22

How to Use Supply Chain Challenges to Win New Business

Given the scramble to address supply chain challenges, this year might be an ideal time for MedTech firms to re-evaluate ways to generate new business.

Estelle Black 3/7/22 Estelle Black 3/7/22

Ukraine - MedWorld Advisors Statement

MedWorld Advisors statement on the situation in Ukraine.

MedWorld Advisors 2/23/22 MedWorld Advisors 2/23/22

Want to end high inflation in 2022?

Uniting to end the labor shortage will slow down MedTech Industry price increases.

MedWorld Advisors 2/14/22 MedWorld Advisors 2/14/22

MedTech Trends in 2022: Headwinds and Tailwinds

The new year begins amid a dramatically different medtech environment than 2021. Although the industry’s future remains bright, a unique set of challenges—or headwinds—awaits the sector in 2022. Fortunately, those headwinds can be conquered by equally unique opportunities, or tailwinds.

Estelle Black 1/21/22 Estelle Black 1/21/22

2021 M&A Review: The MedTech Sector

MedWorld Advisors 2021 M&A Review: The MedTech Sector

Estelle Black 12/21/21 Estelle Black 12/21/21

Ortoma Signs Agreement with J&J K.K. for Exclusive Distribution Rights in Japan, Facilitated by MedWorld Advisors

Ortoma signs agreement with Johnson & Johnson K.K. for exclusive distribution rights in Japan of the Ortoma Treatment Solution for hip surgery. It is the first agreement that the company executes with a global strategic partner. The agreement allows for the possibility to expand the partnership to other global markets.

Dave Sheppard 12/20/21 Dave Sheppard 12/20/21

Preparing for 2022

As we are now moving into 2022, it appears that while 2021 was less volatile than 2020, it certainly has had its own drama which will impact us as we head into a new year. Here are some of the high impact areas affecting the healthcare industry for 2022.

Estelle Black 12/16/21 Estelle Black 12/16/21

Common Mistakes Seller’s Make When Trying to Make Their Exit

Ready to sell? What are some of the common mistakes seller’s often make when trying make their exit? Do you know what they are? And more importantly how can you avoid them?

Estelle Black 12/2/21 Estelle Black 12/2/21

Deja-vu? MedTech M&A Moving Into 2022

Another new variant is coming to life and the uncertainty that has become commonplace in our lives is once again at center stage. What does this uncertainty mean for your business, the Healthcare industry, and mergers and acquisitions in general?

Estelle Black 11/22/21 Estelle Black 11/22/21

MedWorld Advisors @ Medica 2021

MedWorld Advisors at Medica 2021.

MedWorld Advisors 11/10/21 MedWorld Advisors 11/10/21

What’s Next for Medtech’s Top Companies 2022?

It’s an ideal time to reflect upon the 2021 performance of MedTech’s largest OEMs and portend their growth prospects for the coming year.

Estelle Black 11/4/21 Estelle Black 11/4/21

Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID

Revelation Biosciences Inc. engages partnering advisor, MedWorld Advisors, to optimize value of the company’s diagnostic tool, REVID

Dave & Flo 10/25/21 Dave & Flo 10/25/21

Orthopedic Industry Insights and Reflections

We’ve attended the AAOS Annual Meeting many times over the years to gain insights into this $50 billion market (estimated). The meeting has provided valuable data about orthopedic industry trends and its impacts on other healthcare market segments. Clearly, orthopedics is a sector that cannot and should not be ignored.

Estelle Black 10/21/21 Estelle Black 10/21/21

Are We in an M&A Bubble?

Are we in an M&A bubble? And if we are, how will this affect transaction multiples moving into 2022 and beyond? From our recent webinar series MedTech M&A: A Financial Buyer's Perspective, Managing Director - Middle Markets Daniel Sheppard asks this very question to our panel of industry professionals.

Contact us.